Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells 2,066 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) insider Linda Llewelyn sold 2,066 shares of the firm's stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $7.00, for a total value of $14,462.00. Following the completion of the transaction, the insider now owns 124,160 shares of the company's stock, valued at $869,120. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Linda Llewelyn also recently made the following trade(s):

• On Monday, April 15th, Linda Llewelyn sold 2,005 shares of Health Catalyst stock. The stock was sold at an average price of $6.11, for a total value of $12,250.55.

Health Catalyst Stock Down 0.5 %

NASDAQ:HCAT traded down $0.04 on Monday, reaching $6.92. The company's stock had a trading volume of 567,028 shares, compared to its average volume of 637,462. Health Catalyst, Inc. has a 12-month low of $5.45 and a 12-month high of $14.37. The firm has a market cap of $408.19 million, a price-to-earnings ratio of -3.74 and a beta of 1.32. The stock has a 50 day moving average price of $6.81 and a 200 day moving average price of $8.13.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last posted its earnings results on Thursday, February 22nd. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.06. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. The company had revenue of $75.08 million for the quarter, compared to the consensus estimate of $73.67 million. Equities research analysts expect that Health Catalyst, Inc. will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Health Catalyst

A number of institutional investors have recently modified their holdings of the company. Virtus Investment Advisers Inc. acquired a new stake in shares of Health Catalyst in the first quarter valued at $115,000. Kennedy Capital Management LLC acquired a new position in Health Catalyst during the 1st quarter worth $8,780,000. Price T Rowe Associates Inc. MD grew its stake in Health Catalyst by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company's stock worth $375,000 after purchasing an additional 2,831 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Health Catalyst during the 1st quarter worth $98,000. Finally, Acadian Asset Management LLC grew its stake in Health Catalyst by 38.3% during the 1st quarter. Acadian Asset Management LLC now owns 724,560 shares of the company's stock worth $5,453,000 after purchasing an additional 200,494 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HCAT. Wells Fargo & Company reduced their price objective on Health Catalyst from $14.00 to $13.00 and set an "overweight" rating for the company in a research note on Friday, May 10th. Canaccord Genuity Group reduced their price objective on Health Catalyst from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Friday, February 23rd. Guggenheim upgraded Health Catalyst from a "neutral" rating to a "buy" rating and set a $14.00 price objective for the company in a research note on Friday, January 26th. Evercore ISI dropped their target price on Health Catalyst from $11.00 to $10.00 and set an "outperform" rating on the stock in a report on Friday, February 23rd. Finally, KeyCorp reaffirmed a "sector weight" rating on shares of Health Catalyst in a report on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $12.18.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.